Etonogestrel
From Wikipedia, the free encyclopedia
Etonogestrel
|
|
Systematic (IUPAC) name | |
(8S,9R,10S,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one | |
Identifiers | |
CAS number | |
ATC code | G03 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C22H28O2 |
Mol. mass | 324.457 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | Hepatic (P450 3A4) |
Half life | 25 hours |
Excretion | Urinary (majority) and fecal |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status |
Prescription Only (S4)(AU) POM(UK) ℞-only(US) ℞ Prescription only |
Routes | Subdermal as slow-release implant |
Etonogestrel is a molecule used in hormonal contraceptives, most notably the subdermal implant Implanon.
Etonogestrel, the specific progestin used in NuvaRing, is the active metabolite of the inactive prodrug desogestrel, one of two third-generation progestins found in some epidemiological studies of combined oral contraceptive pills to be associated with a higher risk of venous thrombosis than combined oral contraceptive pills containing certain second-generation progestins. Because hormones are released continuously from NuvaRing, peak and total estrogen and progestin doses are significantly lower than with combined oral contraceptives, although it is not known whether this lowers the risk of blood clots.